EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies

Stefano Zoroddu iD, Luigi Bagella iD

Cells · 2025

DOI: 10.3390/cells14181476 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Stefano Zoroddu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43/b, 07100 Sassari, Italy. Hauptthemen laut MEDLINE: Melanoma, Cancer Vaccines, mRNA Vaccines, RNA, Messenger. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) vaccines have redefined cancer immunotherapy, offering unparalleled flexibility to encode tumor-specific antigens and to be adapted to individual mutational landscapes. Melanoma, with its high mutational burden and responsiveness to immune checkpoint blockade, has become the leading model for translating these advances into clinical benefit. Recent innovations in delivery—ranging from lipid nanoparticles and polymeric carriers to biomimetic hybrids and intratumoral administration—are dismantling long-standing barriers of stability, targeting, and immunogenicity. Clinical milestones, including the randomized phase IIb KEYNOTE-942, show that adding the personalized neoantigen vaccine mRNA-4157 (V940) to pembrolizumab prolonged recurrence-free survival versus pembrolizumab alone (HR 0.561, 95% CI 0.309–1.017; 18-month RFS 79% vs. 62%), with the ASCO 3-year update reporting 2.5-year RFS 74.8% vs. 55.6% and sustained distant metastasis-free survival benefit in resected high-risk melanoma. Parallel preclinical studies highlight the potential of multifunctional platforms co-delivering cytokines or innate agonists to reshape the tumor microenvironment and achieve durable systemic immunity. As artificial intelligence drives epitope selection and modular manufacturing accelerates personalization, mRNA vaccines may have the potential to transition from adjuncts to main therapies in melanoma and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaCancer VaccinesmRNA VaccinesRNA, MessengerHumansImmunotherapyAnimals

Stichwörter der Autor:innen

combination therapiesintratumoral deliverylipid nanoparticles (LNPs)mRNA vaccinesmelanoma immunotherapy

Substanzen

Cancer VaccinesmRNA VaccinesRNA, Messenger

Autor:innen und Institutionen

  • Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43/b, 07100 Sassari, Italy.
  • Sbarro Institute for Cancer Research and Molecular Medicine, Centre for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.

ORCID-Profile: Stefano Zoroddu, Luigi Bagella

Zitieren

APA

Zoroddu, S., & Bagella, L. (2025). Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. Cells. https://doi.org/10.3390/cells14181476

Vancouver

Zoroddu S, Bagella L. Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. Cells. 2025. doi:10.3390/cells14181476

BibTeX
@article{Zoroddu2025,
  author = {Zoroddu, Stefano and Bagella, Luigi},
  title = {Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14181476}
}
Kostenlos starten →